Trial reportPediatric research2025
Bronchopulmonary dysplasia to predict neurodevelopmental impairment in infants born extremely preterm.
Trial report in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00623740 (Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial
Who cites it
4 citing papers in PubMed.
- Identifying predictors of tracheostomy or death in preterm infants with grade 3 BPD.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- A nomogram to predict bronchopulmonary dysplasia in very preterm and/or very low birth weight infants with early-onset sepsis.BMC pediatrics · 2026Observational
- Impact of LISA failure on 2-year neurodevelopmental outcomes in preterm infants: a retrospective cohort study.BMJ paediatrics open · 2025Article
- Prophylactic low-dose hydrocortisone in neonates born extremely preterm: current knowledge and future challenges.Pediatric research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchopulmonary dysplasia (BPD) in extremely low gestational age neonates (ELGANs) was associated with neurodevelopmental impairment (NDI). However, the best endpoint of BPD assessment to predict subsequent NDI remains unclear.
methodsWe re-analyzed the PREMILOC trial, previously designed to test the effect of prophylactic hydrocortisone on survival without BPD at 36 weeks of postmenstrual age (BPD
resultsAmong 404/519 (77.8%) infants enrolled in the trial alive at 2 years of age, all neurocognitive scores were available for 302 (74.8%) patients. Gestational diabetes and sex were identified as the only statistically significant baseline predictors of NDI. Adding BPD
conclusionsThese data suggest a better accuracy of BPD REGISTRATION NUMBERS: EudraCT number 2007-002041-20, ClinicalTrial.gov number, NCT00623740. IMPACT: The best endpoint to assess BPD as a surrogate to predict neurocognitive impairment in infants born extremely preterm remains unclear. This study strongly suggests a better discriminative value of BPD as assessed at 40 weeks of postmenstrual age (instead of 36 weeks) to predict neurocognitive impairments at 2 years of age in children born extremely preterm. This study supports the switch up to 40 weeks of the primary outcome chosen in future clinical trials designed to prevent BPD. Our data also provide evidence of the beneficial effect of HC on preventing BPD at full-term equivalent age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.